US judge denies injunction to stop bar on copies of Lilly weight loss drug
Portfolio Pulse from
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to continue making copies of Eli Lilly's weight-loss drug, Zepbound. This decision supports Eli Lilly's control over the drug's distribution.
March 06, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
A U.S. judge's decision to deny an injunction supports Eli Lilly's control over its weight-loss drug Zepbound, potentially protecting its market share and revenues.
The judge's decision prevents compounding pharmacies from making copies of Zepbound, which could protect Eli Lilly's market share and revenue from this drug. This legal support is likely to have a positive short-term impact on Eli Lilly's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90